Frontiers in Medicine最新文献

{"title":"Editorial: Reviews in: pulmonary medicine 2023.","authors":"Roberto G Carbone, Francesco Puppo","doi":"10.3389/fmed.2025.1589992","DOIUrl":"https://doi.org/10.3389/fmed.2025.1589992","url":null,"abstract":"","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1589992"},"PeriodicalIF":3.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives in clinical research on Azathioprine for steroid-dependent ulcerative colitis.","authors":"Yuan-Ting Qu, Jia-Yuan Ding, Wei Pan, Fang-Rui Liu, Ai-Lian Dong","doi":"10.3389/fmed.2025.1551906","DOIUrl":"https://doi.org/10.3389/fmed.2025.1551906","url":null,"abstract":"<p><p>This study explores the application of Azathioprine in the treatment of ulcerative colitis (UC) and the challenges associated with its long-term use. While short-term studies demonstrate the efficacy of Azathioprine in steroid-dependent UC, long-term data on its risks, including malignancies, infections, and chronic toxicity, remain insufficient. Furthermore, the impact of Azathioprine on patients' quality of life over extended periods is still unclear. The research highlights the importance of optimizing Azathioprine dosing based on genomic data, particularly through TPMT and NUDT15 genotyping, to minimize adverse effects. However, further research is needed to develop individualized treatment strategies that can improve efficacy and reduce toxicity. The identification of predictive biomarkers, through genomics and proteomics, is likely to play a crucial role in improving treatment precision by identifying patients who are most likely to benefit from Azathioprine therapy. Additionally, combining Azathioprine with biologic therapies (such as anti-TNF agents or integrin inhibitors) and interventions targeting the gut microbiome may enhance the drug's effectiveness while reducing reliance on steroids. Overall, large-scale clinical trials are urgently needed to evaluate the benefits and risks of these emerging therapies, ultimately supporting more personalized treatment approaches for steroid-dependent UC patients.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1551906"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Jinghua Weikang capsule combined with amoxicillin-furazolidone triple/quadruple therapies in the rescue treatment of <i>Helicobacter pylori</i> infection.","authors":"Yao Yang, Xin Deng, Hui-Xia Xiao, Su-Man Ye, Zi-Cheng Wang, Feng Jiang, Hai-Xiao Han, Zai-Jian Wang, Ji-Zheng Ma, Yu Lan, Hui Ye, Xue-Zhi Zhang","doi":"10.3389/fmed.2025.1531620","DOIUrl":"https://doi.org/10.3389/fmed.2025.1531620","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy and safety of Jinghua Weikang Capsule (JWC) combined with amoxicillin-furazolidone triple/quadruple therapies in the rescue treatment of drug-resistant <i>H. pylori</i> infection.</p><p><strong>Methods: </strong>Patients who failed <i>H. pylori</i> eradication therapy at least once were enrolled and randomly assigned into four groups (1:1:1:1), as follows: The control group received 20 mg rabeprazole, 1,000 mg amoxicillin, 220 mg bismuth potassium citrate, and 100 mg furazolidone twice daily (b.i.d.) for 14 days; Group A received 240 mg JWC b.i.d. combined with 20 mg rabeprazole, 1,000 mg amoxicillin, and 100 mg furazolidone b.i.d. for 14 days; Group B received the same regimen as Group A for 14 days, followed by an additional 14 days of 240 mg JWC b.i.d.; and Group C received 240 mg JWC b.i.d. combined with 20 mg rabeprazole, 1,000 mg amoxicillin, 220 mg bismuth potassium citrate, and 100 mg furazolidone b.i.d. for 10 days. The primary outcome was <i>H. pylori</i> eradication at 4 weeks after treatment.</p><p><strong>Results: </strong>Four hundred eighty-eight patients were included in this study. The intention-to-treat (ITT) eradication rates in the four groups were 85.2, 73.8, 78.7 and 75.4% (<i>p</i> = 0.136), while the modified intention-to-treat (MITT) eradication rates were 92.0, 84.9, 88.9 and 86.8% (<i>p</i> = 0.398), respectively. And the per-protocol (PP) eradication rates were 92.5, 85.4, 87.9 and 86.7% (<i>p</i> = 0.405), respectively. The eradication rates were comparable among the four groups. No statistically significant differences in eradication rates were observed between each of the three treatment groups and the control group (all <i>p</i> > 0.05). The eradication rate of <i>H. pylori</i> in group B demonstrated non-inferiority compared with the control group (<i>p</i> = 0.0415; 90% CI, -0.0965 to 0.0336). The four groups exhibited similar frequencies of overall adverse events (9.84, 5.74, 6.56%, 2.46%, <i>p =</i> 0.112).</p><p><strong>Conclusion: </strong>The eradication rate of the JWC-containing regimen demonstrated no statistically significant difference compared with bismuth-containing quadruple therapy in the rescue treatment of <i>H. pylori</i> infection. The prolonged JWC treatment regimen exhibited non-inferiority in eradication rates. JWC-containing therapies can effectively reduce the incidence of adverse reactions and significantly alleviate certain clinical symptoms.</p><p><strong>Clinical trial: </strong>https://clinicaltrials.gov/, identifier ChiCTR1800019326.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1531620"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year changes in axial length and refraction in children using low-level red light and distant-image screen for myopia control: a randomized controlled trial.","authors":"Ke Yang, Yuhan Wang, Xiaoxia Li, Sumeng Liu, Hui Shi, Liya Qiao","doi":"10.3389/fmed.2025.1542620","DOIUrl":"https://doi.org/10.3389/fmed.2025.1542620","url":null,"abstract":"<p><strong>Objective: </strong>To assess the efficacy and safety of 650-nm low-level red light (RL) and distant-image therapy (DIT) for myopia.</p><p><strong>Methods: </strong>A randomized clinical trial. Children aged 8-10 years with a spherical equivalent error (SER) ranging from -1 to -1.5 diopters (D) were enrolled, and were randomly allocated to the following group: RL, DIT, RL + DIT, and control in a 1:1:1:1 ratio. The primary outcomes were changes in SER and axial length (AL).</p><p><strong>Results: </strong>One hundred and sixteen children randomized, girls accounted for 45.69% (53/116). The median one-year changes in SER were 0.21D (inter-quartile range, IQR: -0.03D to 0.46D), -0.06D (-0.32D to 0.19D), -0.08D (-0.31D to 0.14D), and -0.30D (-0.51D to -0.09D), respectively, for the RL + DIT, RL, DIT, and the control group. The median one-year changes in AL were 0.04 mm (-0.03 mm to 0.13 mm), 0.05 mm (-0.03 mm to 0.14 mm), 0.30 mm (0.22 mm to 0.37 mm), and 0.42 mm (0.35 mm to 0.49 mm), respectively, for the RL + DIT, RL, DIT, and the control group. Fundus photographs revealed no retinal changes across all groups.</p><p><strong>Conclusion: </strong>Participants who underwent daily 650-nm low-level red light therapy combined with distant-image screen intervention for 12 months demonstrated a significant deceleration in myopia progression, with 79.3% exhibiting potential for reversal of myopia. No safety concerns were identified through OCT and fundus photography.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, NCT06683287.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1542620"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Fontan-associated liver disease: current status and future directions.","authors":"Ornella Milanesi, Oktay Tutarel, Annalisa Angelini","doi":"10.3389/fmed.2025.1575638","DOIUrl":"https://doi.org/10.3389/fmed.2025.1575638","url":null,"abstract":"","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1575638"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of traumatic subluxation of the crystalline lens with custom-made capsular hook.","authors":"Ning Li, Jie Dong, Jianfeng Wang, Xiaohui Ren, Juanjuan Guo, Juan Li, Ziqing Gao","doi":"10.3389/fmed.2025.1569767","DOIUrl":"https://doi.org/10.3389/fmed.2025.1569767","url":null,"abstract":"<p><strong>Objective: </strong>Traumatic rupture of the lens zonules, leading to lens dislocation, is common in clinical practice and often requires surgical treatment. We aim to study capsular hooks, formed from 5-0 or 6-0 polypropylene sutures by heat shaping, to fix the capsular bag and reshape the lens zonular.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 16 patients (16 eyes) with traumatic subluxation of the crystalline lens who visited our department. Capsular hooks were fabricated using 5-0 or 6-0 polypropylene sutures, shape by heat, to fix the anterior capsular opening. The sutures passed out of the eye, punctured the sclera and traversed it parallel to the limbus for 2-3 mm, exiting through the conjunctiva to form a suture tunnel parallel to the limbus, securing the suture and preventing loosening. Changes in best-corrected visual acuity (BCVA) after surgery, intraocular lens centration, and surgical complications were assessed.</p><p><strong>Results: </strong>Post-operative follow-up was 6-30 months, with an average of 10 ± 5.9 months. The BCVA improved from a pre-operative median of 2.15 (1.67) logMAR to a postoperative median of 0.25 (0.38) logMAR (paired sample Wilcoxon signed-rank test, <i>Z</i> = 3.516, <i>p</i> < 0.001). Postoperatively, the intraocular lenses were well-centered, the capsular bags were securely fixed, and no capsular hooks dislodgement occurred. One patient experienced combined vitreous hemorrhage during surgery. Another patient (case 2) developed rhegmatogenous retinal detachment 2 years post-surgery. After pars plana vitrectomy, the retina was reattached, and the final visual acuity remained stable.</p><p><strong>Conclusion: </strong>Long-term follow-up data suggest that using custom-made capsular hooks offers a reliable solution for maintaining long-term stability of the capsular bag in patients with traumatic crystalline lens subluxation. This technique maintains the centering of the IOL postoperatively, showing effectiveness and safety, and it holds potential for broader clinical application.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1569767"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.","authors":"Hiroo Fukada, Kazuyoshi Kon, Reiko Yaginuma, Akira Uchiyama, Maki Morinaga, Kei Ishizuka, Kyoko Fukuhara, Hironao Okubo, Satoko Suzuki, Shuko Nojiri, Shunhei Yamashina, Kenichi Ikejima","doi":"10.3389/fmed.2025.1542741","DOIUrl":"https://doi.org/10.3389/fmed.2025.1542741","url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacotherapy for metabolic dysfunction-associated steatotic liver disease (MASLD) is still under development and has not been fully established. For patients with MASLD and type 2 diabetes, treatment with antidiabetic drugs, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, is recommended, with vitamin E supplementation when treatment efficacy is insufficient. The benefits and risks of SGLT2 inhibitors for MASLD with type 2 diabetes have not been thoroughly investigated.</p><p><strong>Objective: </strong>This prospective randomized controlled trial aimed to elucidate the effectiveness and risks of the SGLT2 inhibitor dapagliflozin in comparison with vitamin E in patients with MASLD and comorbid type 2 diabetes.</p><p><strong>Methods: </strong>The trial enrolled 24 patients with MASLD and comorbid type 2 diabetes, who were assigned to receive either dapagliflozin (5 mg/day) or vitamin E (150 mg/day) for 24 weeks. The primary outcomes included serum levels of AST, ALT, γ-GT, and type IV collagen, and the FIB-4 index. The secondary outcomes were BMI, HbA1c and serum ferritin levels, lipid profile, body composition assessed using InBody, and hepatic fat content and fibrosis evaluated with FibroScan. Adverse events were monitored throughout the study period.</p><p><strong>Results: </strong>Both groups demonstrated significant reductions in serum AST and ALT levels but intergroup differences were not significant. The dapagliflozin group showed additional benefits, with significant decreases in BMI and HbA1c, γ-GT, ferritin, LDL cholesterol, and body fat levels, indicating improved glycemic control and lipid profile. Dapagliflozin administration was associated with a significant decline in the skeletal muscle index, indicating a risk of muscle loss absent in the vitamin E group. This reduction in muscle mass is clinically significant as it suggests a potential risk of worsened overall survival with dapagliflozin treatment.</p><p><strong>Conclusion: </strong>This study indicates that dapagliflozin provides several metabolic benefits in patients with MASLD and comorbid type 2 diabetes, including reductions in the levels of liver enzymes and body fat, but the observed decrease in muscle mass suggests a potential adverse effect on long-term survival outcomes. Muscle mass should be monitored in patients receiving dapagliflozin therapy to mitigate the risk of sarcopenia progression and ensure a comprehensive approach to MASLD management.</p><p><strong>Clinical trial registration: </strong>https://jrct.niph.go.jp/re/reports/detail/81182, identifier jRCT1031180386.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1542741"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal conbercept for chronic central serous chorioretinopathy with occult CNV: a retrospective clinical study based on multimodal ophthalmic imaging.","authors":"Suyu Wang, Jiajun Li, Zhipeng Yan, Qin Jiang, Keran Li","doi":"10.3389/fmed.2025.1550543","DOIUrl":"https://doi.org/10.3389/fmed.2025.1550543","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the therapeutic efficacy and safety of intravitreal conbercept in patients with chronic central serous chorioretinopathy (cCSC) complicated by occult choroidal neovascularization (CNV), and to explore its potential in improving visual function and various ophthalmic parameters.</p><p><strong>Methods: </strong>This retrospective, longitudinal, comparative study included 50 patients diagnosed with cCSC and occult CNV. Patients underwent intravitreal conbercept injections and were monitored over a six-month period. Comprehensive ophthalmic evaluation included best-corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF) status, subfoveal choroidal thickness (SFCT), and optical coherence tomography angiography (OCTA). OCTA parameters such as foveal avascular zone (FAZ) area and CNV lesion characteristics were analyzed pre- and post-treatment. Patients were categorized based on changes in CNV lesion size to identify prognostic factors influencing treatment response.</p><p><strong>Results: </strong>Significant improvements were observed in mean BCVA from baseline (0.78 ± 0.50 vs. 0.32 ± 0.31, <i>p</i> < 0.01) in all 50 eyes of the patients, except for one eye. Additionally, there were significant improvements in CMT, SRF status, SFCT, FAZ area, and CNV lesion size post-treatment (<i>p</i> < 0.05). Pearson correlation analysis indicated a positive correlation between baseline BCVA and CMT (<i>r</i> = 0.3615, <i>p</i> = 0.0116). Changes in BCVA post-treatment correlated with alterations in CMT, SRF diameter, and CNV lesion size. Patients with a favorable treatment response had significantly lower baseline CMT (312.17 ± 57.39 vs. 428.86 ± 114.54, <i>p</i> < 0.05) and CNV vessel diameter (17.46 ± 2.72 vs. 24.84 ± 4.02, <i>p</i> < 0.01) compared to those with unfavorable responses.</p><p><strong>Conclusion: </strong>Intravitreal conbercept injection was found to be safe and effective in improving BCVA and various ophthalmic parameters in patients with cCSC complicated by occult CNV, with no significant adverse effects observed during the study period. Baseline CMT, SRF diameter, CNV lesion size, and mean CNV vessel diameter were identified as valuable indicators for assessing treatment response and prognosis. These findings provide important insights for the clinical management and prognostic evaluation of cCSC patients with occult CNV, highlighting the utility of multimodal imaging in assessing treatment outcomes.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1550543"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the giants: a bibliometric analysis of the top 100 most-cited thyroid nodules studies.","authors":"Xinfeng Zhou, Mingjun Liu, Tianjiao Gao, Yi Tan, Xiao Wang, Long Yang, Shengxian Xu, Rui Wang, Haoyang Gao, Shaotao Chen","doi":"10.3389/fmed.2025.1555676","DOIUrl":"https://doi.org/10.3389/fmed.2025.1555676","url":null,"abstract":"<p><strong>Background: </strong>Thyroid disease continues to be one of the most prevalent disease groups worldwide, with its frequency and distribution being impacted by numerous factors. Significant progress has been achieved in recent years in thyroid nodules, largely due to the advent of novel detection and diagnostic techniques. This study aims to scrutinize the top 100 most frequently cited articles in thyroid nodule research, utilizing bibliometric analysis to identify trends, highlight critical focal points, and lay a groundwork for forthcoming investigations.</p><p><strong>Methods: </strong>A comprehensive literature search was carried out using the SCI-E database, and all the recorded results were downloaded in plain text format for detailed analysis. The key terms analyzed with VOSviewer 1.6.18, CiteSpace 6.3r1, bibliometrix in R Studio (v.4.4.1), and Microsoft Excel 2021 software include country, institution, author, journal, and keywords.</p><p><strong>Results: </strong>The publication timeframe extends from 1 January 2003 to 31 December 2021, reaching a peak citation count of 9,100. Notably, the United States leads in the number of published articles, with Harvard University standing out as a prestigious institution. These articles were featured in 45 diverse journals, with THYROID leading in publication volume. Nikiforov Yuri E. was the most prolific first author, appearing 10 times. Keyword analysis highlighted traditional research themes such as \"fine needle aspiration,\" \"carcinogens,\" and \"management.\" However, \"deep learning\" has surfaced as a significant area of focus in recent studies.</p><p><strong>Conclusion: </strong>This study has extracted the bibliometric characteristics of the top 100 most-cited articles pertaining to TNs, providing an invaluable reference for upcoming studies. Through meticulous analysis, it has been determined that the primary research concentrations encompass the diagnosis of benign or malignant TNs, the management of TNs, and the subsequent monitoring of TNs, with deep learning emerging as a pivotal area of exploration.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1555676"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging role of intestinal stem cells in ulcerative colitis.","authors":"Siqing Chen, Zhang Qin, Sainan Zhou, Yin Xu, Ying Zhu","doi":"10.3389/fmed.2025.1569328","DOIUrl":"https://doi.org/10.3389/fmed.2025.1569328","url":null,"abstract":"<p><p>Ulcerative colitis (UC) is a chronic idiopathic inflammatory disease affecting the colon and rectum. Characterized by recurrent attacks, UC is often resistant to traditional anti-inflammatory therapies, imposing significant physiological, psychological, and economic burdens on patients. In light of these challenges, innovative targeted therapies have become a new expectation for patients with UC. A crucial pathological feature of UC is the impairment of the intestinal mucosal barrier, which underlies aberrant immune responses and inflammation. Intestinal stem cells (ISCs), which differentiate into intestinal epithelial cells, play a central role in maintaining this barrier. Growing studies have proved that regulating the regeneration and differentiation of ISC is a promising approach to treating UC. Despite this progress, there is a dearth of comprehensive articles describing the role of ISCs in UC. This review focuses on the importance of ISCs in maintaining the intestinal mucosal barrier in UC and discusses the latest findings on ISC functions, markers, and their regulatory mechanisms. Key pathways involved in ISC regulation, including the Wnt, Notch, Hedgehog (HH), Hippo/Yap, and autophagy pathways, are explored in detail. Additionally, this review examines recent advances in ISC-targeted therapies for UC, such as natural or synthetic compounds, microbial preparations, traditional Chinese medicine (TCM) extracts and compounds, and transplantation therapy. This review aims to offer novel therapeutic insights and strategies for patients who have long struggled with UC.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1569328"},"PeriodicalIF":3.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}